Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The price of Zymeworks BC Inc (NASDAQ: ZYME) closed at $17.9 in the last session, down -0.83% from day before closing price of $18.05. In other words, the price has decreased by -$0.83 from its previous closing price. On the day, 1.16 million shares were traded. ZYME stock price reached its highest trading level at $18.23 during the session, while it also had its lowest trading level at $17.565.
Ratios:
We take a closer look at ZYME’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.69 and its Current Ratio is at 7.69. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
On October 14, 2025, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $26.
On October 10, 2025, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $30.B. Riley Securities initiated its Buy rating on October 10, 2025, with a $30 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 15 ’25 when EcoR1 Capital, LLC bought 49,502 shares for $11.43 per share. The transaction valued at 565,847 led to the insider holds 17,877,989 shares of the business.
EcoR1 Capital, LLC bought 5,919 shares of ZYME for $69,738 on May 19 ’25. The Director now owns 17,883,908 shares after completing the transaction at $11.78 per share. On Apr 16 ’25, another insider, EcoR1 Capital, LLC, who serves as the Director of the company, bought 73,953 shares for $11.16 each. As a result, the insider paid 825,589 and bolstered with 17,773,727 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZYME now has a Market Capitalization of 1355663360 and an Enterprise Value of 1082773888. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.03 while its Price-to-Book (P/B) ratio in mrq is 4.04. Its current Enterprise Value per Revenue stands at 8.813 whereas that against EBITDA is -14.913.
Stock Price History:
The Beta on a monthly basis for ZYME is 1.31, which has changed by 0.085387826 over the last 52 weeks, in comparison to a change of 0.13355756 over the same period for the S&P500. Over the past 52 weeks, ZYME has reached a high of $19.98, while it has fallen to a 52-week low of $9.03. The 50-Day Moving Average of the stock is 5.77%, while the 200-Day Moving Average is calculated to be 29.08%.
Shares Statistics:
According to the various share statistics, ZYME traded on average about 653.07K shares per day over the past 3-months and 1031880 shares per day over the past 10 days. A total of 74.85M shares are outstanding, with a floating share count of 73.13M. Insiders hold about 3.44% of the company’s shares, while institutions hold 102.12% stake in the company. Shares short for ZYME as of 1760486400 were 7047624 with a Short Ratio of 10.79, compared to 1757894400 on 7156267. Therefore, it implies a Short% of Shares Outstanding of 7047624 and a Short% of Float of 11.91.
Earnings Estimates
The stock of Zymeworks BC Inc (ZYME) is currently in the spotlight, with 9.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.24, with high estimates of $0.36 and low estimates of -$0.88.
Analysts are recommending an EPS of between $0.01 and -$1.63 for the fiscal current year, implying an average EPS of -$0.86. EPS for the following year is -$1.03, with 10.0 analysts recommending between $0.31 and -$2.02.
Revenue Estimates
According to 8 analysts,. The current quarter’s revenue is expected to be $29.91M. It ranges from a high estimate of $53.6M to a low estimate of $18M. As of. The current estimate, Zymeworks BC Inc’s year-ago sales were $16MFor the next quarter, 8 analysts are estimating revenue of $35.45M. There is a high estimate of $93.6M for the next quarter, whereas the lowest estimate is -$8M.
A total of 6 analysts have provided revenue estimates for ZYME’s current fiscal year. The highest revenue estimate was $136M, while the lowest revenue estimate was $86M, resulting in an average revenue estimate of $116.75M. In the same quarter a year ago, actual revenue was $76.3MBased on 10 analysts’ estimates, the company’s revenue will be $153M in the next fiscal year. The high estimate is $313.26M and the low estimate is $89.28M.
